Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Lebanon Sci-Tech Weekly.
Press releases published on October 13, 2025
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
374Water to Host Third Quarter 2025 Results Conference Call on Wednesday, November 12, 2025 at 4:30 p.m. Eastern Time
DURHAM, N.C., Oct. 13, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) (“374Water” or the “Company”), a global leader in organic waste destruction technology and services for the municipal, federal, and industrial markets, will hold a conference call …
Landis+Gyr Taps SEALSQ for Enhanced Smart Grid Network Security in North America
Geneva, Switzerland and Atlanta, GA, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Watch Times Square video here: https://youtu.be/0eKNhLhOTGo SEALSQ PKI solution being implemented for electric and gas smart grid devices SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or " …
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
Myseum Awarded Israeli Patent for Advanced Digital Privacy Technology
NEW BRUNSWICK, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Myseum, Inc. (Nasdaq: MYSE) (“Myseum” or the “Company”), a privacy-first social media and technology company, today announced that the Israel Patent Office has granted patent no. 290546 for the Company …
Third Millennium Unveils Multi-Technology Readers Combining Card and QR Code Access in One Device
Pontypool, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Third Millennium, a provider of access control solutions and part of HID, announces the launch of new RXQR and RXQRK readers — multi-technology access-control devices that integrate high-security RFID card and …
Auron Therapeutics to Participate in the 8th Annual Targeted Protein Degradation & Induced Proximity Summit
NEWTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that members of its leadership …
Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
Presentation will cover two-year clinical efficacy, immunogenicity and safety data Data will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing further insights into the clinical findings COPENHAGEN, …
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025
NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management team will ring the Nasdaq opening bell on October 14, 2025 at 9:30 a.m. ET in celebration of its 10-year anniversary as a …
Hinge Bio Announces FDA Clearance of Investigational New Drug Application for HB2198, a Novel B cell-Depleting Agent, for Patients with Systemic Lupus Erythematosus and Lupus Nephritis
BURLINGAME, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held biotechnology company engaged in the discovery and development of innovative multi-specific medicines, announced the U.S. Food and Drug Administration (“FDA”) has …
HMNC Brain Health Presents New Analysis Supporting Rationale for Combining a Genetic Patient Selection Tool with a Vasopressin V1b Receptor Antagonist in the Treatment of Depression at ISCTM Conference in Amsterdam
MUNICH, Oct. 13, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health, a clinical-stage precision psychiatry biopharmaceutical company developing personalized treatments powered by predictive companion diagnostics, today announced it presented a retrospective …
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will be presenting late- …
MKS Inc. Announces Third Quarter 2025 Earnings Conference Call
ANDOVER, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- MKS Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that the Company will release third quarter 2025 financial results after market close on …
Nuvini Announces Open-Market Stock Purchases by Key Executives
~ Open Market Buys with Personal Funds~ NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading acquirer and operator of vertical market SaaS businesses in Latin America, today announced that …
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis, following program and clinical data review by its independent scientific advisors Funding supports second 4D-710 dosing …
Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings
- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 - - SYN-004 Interim blinded safety and pharmacokinetic data to be presented at IDWeek 2025 - Rockville, Md., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE …
Theriva™ Biologics anuncia próximas ponencias en congresos médicos
- Los datos ampliados del mPDAC del ensayo VIRAGE de fase 2b sobre el VCN-01 se presentarán en la ESMO 2025. - Los datos provisionales sobre seguridad y farmacocinética de SYN-004 se presentarán en IDWeek 2025. ROCKVILLE, Md., Oct. 13, 2025 (GLOBE NEWSWIRE …